We have developed a quantitative system to measure serum concentrations of the soluble form of human IGF-II receptor (IGF-IIR). The soluble form retains the ability to bind to IGF-II and proteins with M6P moieties in circulating blood. IGF-IIR does not only control the degradation of IGF-II, but also inhibits DNA synthesis by modifying the IGF-II action. The measurement of serum concentrations of the soluble form is able to clarify the growth mechanism in vivo. The system employs an enzyme immunoassay (EIA) making use of antibodies to peptides 1103~1119 amino acid (AA) of IGF-IIR. We could obtain two single bands at about 220 kDa corresponding to the soluble form and at about 290 kDa corresponding to the cell membrane-associated form by Western blotting. According a recent report, the soluble form was 220 kDa, and the measured level was 700 ± 230 ng/ml in healthy adults. In our trial data, the measured mean level was about 724 ± 134 ng/ml in five healthy adults. These data were nearly coincident. Consequently this antibody has high specificity for the soluble form in blood and the cell membrane associated form of IGF-IIR.
Introduction
IGF-II receptor (IGF-IIR) is a glycoprotein composed of 2491 AA, with a molecular weight of about 290 kDa. It is a single-chain receptor, which traverses the cell membrane once.
The molecule of IGF-IIR has 15 repeats of a homologous 150AA sequence in the extra cellular domain (1, 7, 8) , which accounts for 90% of its total length. It was recently shown that the molecular structure of IGF-IIR is identical to that of mannose-6-phosphate receptor (M6P-R) (3) (4) (5) (6) . Moreover, it was confirmed that the extracellular domain of IGF-IIR flowed in circulating blood (9) (10) (11) . It has been called the soluble form of IGF-IIR, whose molecular weight is about 220 kDa, and which is detected in serum from a variety of mammalian species. Truncation of IGF-IIR in the transmembrane region leads to the formation of the soluble form (9) . In this paper, we report on our recent study on the development of a quantitative system for the soluble IGF-IIR based on a competitive enzyme immunoassay with the antibody to the peptide of IGF-IIR.
Materials and Methods
Two Japanese white female rabbits were used for each antigen. Their body weights were 2.5~3 kg. In each immunization session, the rabbits were given Ketamine Hydrochloride (25 mg) and Xylazine (5 mg) before starting the immunizing injections.
Through a Genome Net computer search, we selected three parts suitable as antigens from the extracellular domain of human IGF-IIR cDNA (7~22AA, 1103~1119AA, and 2046~2064AA), for automatical synthesis of the peptides. The criteria used for the selection included: 1) a threedimensional structure with outward protrusion, 2) an isoelectric point of 11~12 (to allow production of a neutral and aqueous injectable solution to minimize skin sensitivity), 3) rich in aromatic amino acids, and 4) absence of similar sequences in the genome of the rabbits to be immunized.
Many synthetic peptides combine with a carrier protein (poly-L lysine, about 100 kDa). The total antigen molecule is approximately 140 kDa. The poly-L lysine has multiple protrusions constituting of the peptides on its surface. The antigen was next mixed with an adjuvant. The amount of antigen used for each immunization session was 0.5 mg/2 ml. Each antigen was administered to Japanese white rabbits. Each immunization session consisted of intra-dermal injection of the antigen (10 µg /site) at 50 sites on the shaved skin (10 cm 2 ) of the rabbits. Seven immunization sessions were performed at intervals of 2 weeks ( Fig. 1 ). Blood samples were obtained before and one week after each session to check for high antibody titers by ELISA. Eight days after the last session, we collected the total blood volume and checked for final antibody titers by ELISA. A 96-well plate was coated with the same peptide as that used for the immunization (5 µg/ ml, 50 µl/well). The obtained rabbit serum containing anti-peptide antibody was diluted with PBS and added to each well on the plate (50 µl/ well). Anti-rabbit IgG antibody labeled with horseradish peroxidase (HRP) was then added, followed by the addition of a color developer (TMB + DAKO). The absorbance at 450 nm was measured with a microplate reader. The method for immunizing rabbits with the peptides 1~3 of IGF-IIR. Each peptide was mixed with adjuvant to yield a solution for a single dose (0.5 mg antigen/2 ml). The antigen solution was intradermally injected at 50 points in the shaved skin (10 cm 2 ) of each rabbit (10 mg antigen/point). Sampled blood was checked for antibody titer.
Purification of anti-human IGF-IIR peptide antibodies
Purification with protein-G: Salting-out was first conducted with 4.05 M neutral saturated ammonium sulfate. This was followed by dialysis with 10 mM PBS (pH 7.2). Rabbit antiserum directed against the human IGF-IIR peptide obtained was applied to Protein-G Sepharose FF (Amersham Pharmacia Biotech) to cause IgG antibody adsorption onto the column. Then the IgG fraction was eluted with 100 mM glycine-HCl (pH 2.5). Dialysis with 10 mM PBS (pH 7.2) and 0.15 M NaCl was performed to obtain purified IgG.
Adsorption and purification with PLLsepharose: Antibodies to poly-L-lysine used as the carrier protein binding with the human IGF-IIR peptide were removed as follows. Purified IgG antibody was first applied to the PLL-bound Sepharose column with 10 mM PBS (pH 7.2). After confirming adequate adsorption, the pass through fraction was obtained.
Qualitative analysis by Western blotting: SDS-PAGE was performed with a human placentaderived acetone powder solution. The gel obtained was subjected to Western blotting to induce transfer onto the nitrocellulose membrane (170 mA, 60 min). The membrane was washed in PBS and blocked with 25% Block Ace (Dainippon Pharmaceutical Co., 2 h at room temperature). It was then washed with 0.05% Tween 20-PBS, first exposed to a 1:500 dilution of purified antibody (4 C, 15~18 h), washed once again in 0.05% Tween 20-PBS, and exposed to a 1:3000 dilution of HRPlabeled anti-rabbit IgG (6 h at room temperature). After being washed once again in 0.05% Tween 20-PBS, it was finally exposed to 4-chloro-1-naphthol in diethyleneglycol for color development (20 min at room temperature) ( Fig. 2) .
Establishing a quantitative analysis system
Preparation of human placenta-derived acetone powder and purification of IGF-IIR: The connective tissue surrounding the placenta (which was taken from the animal immediately after labor) was removed. The placenta was cut into 1 cm-square pieces and immediately frozen at -80 C, dissolved in a solution (pH 5, 1.5 l) containing 0.5 mM CaCl 2 and 1 mM NaHCO 3 , supplemented with various protease inhibitors (10 mM Na 2 EDTA, 100 m M 6 -a m i n o h e x a n o i c a c i d , 1 0 m M Nethylmaleimide, 1 mM benzamidine-HCl, 1mM phenylmethylsulfonyl fluoride). The mixture was i mmed ia tel y agi ta ted wit h a mix er a nd centrifuged. The sediment was dissolved in acetone (-20 C, 2.5 l), which was applied to a filter paper (Whatman, 3 MM) in a Buechner funnel for filtration by aspiration. The filter was first washed with acetone (-20 C, 2.5 l) and then with ether (-70 C, 2 l) by continued aspiration. The filtrate was dried and solidified to yield acetone powder, which was dissolved in buffer A (20 mM Tris-HCl, 0.5M NaCl, 0.1% Triton X-100, 500 KIU/ml Aprotinin; pH 7.4), and agitated overnight (4 C). The mixture was centrifuged at 1800-g for 30 min at 4 C. The supernatant was filtered (0.45 µm filter), and the sample applied to on M6P-affinity chromatography column (M6-P-Sepharose 4B column, Amersham Pharmacia Biotech). The absorbance of each fraction at 280 nm was measured. There were two sub-fractions of M6P-R. The larger one (Fractions 6-12) was 290 kDa, which corresponded to the IGF-IIR, and the smaller one was 46 kDa. The larger one was used for plate coating and dilution for the preparation of a standard curve in the present study. EIA (competitive system) protocol and standard curve: The purified human placentaderived IGF-IIR (total protein 25 µg/ml, pH 8.5, 50 µl/well) mentioned above was coated onto the plate (one hour at 37 C), followed by blocking with 25% Block Ace overnight at 4 C. Sample serum, diluted 1:50 with buffer B (20 mM Tris-HCl, 0.15N NaCl, pH 7.4, 0.1%TritonX-100, 0.2%BSA, 0.05%NaN 3 ) was then applied (50 µl/well). Anti 1103~1119AA antibody, whose antibody titer was the highest of the three antibodies obtained, was labeled with biotin and diluted 1:200 with buffer B. This was applied to the sample (50 µl/well), followed by incubation at 4 C overnight. HRPlabeled avidin, diluted 1:5000 with buffer B, was then applied to each well (100 µl/well, room temperature, 30 min). Finally, TMB (100 µl/well) was applied. The reaction was stopped by the addition of 1M H 2 SO 4 (100 µl/well), and the absorbance at 450 nm was measured. In the control group, human placenta-derived purified IGF-IIR was used instead of a serum sample and serially diluted with buffer B according to the same protocol as that described above, and a standard curve representing the relationship between the IGF-IIR level and absorbance was obtained ( Fig. 4) .
Checking of antibody-treated serum for the soluble IGF-IIR: This experiment was conducted according to the method used for the qualitative analysis of the antibodies obtained in this study. First, human serum was subjected to SDS electrophoresis and transferred by Western blotting to the membrane. The membrane was exposed to a 1:500 dilution of anti 1103~1119AA antibodies. Anti-IgG-HRP labeled antibody, diluted 1:3000, was then added to the sample. Color was d e v e l o pe d w it h 4 -c h lo r o -1 -n a ph t h o l in diethyleneglycol ( Fig. 5 ).
Results
An increase in rabbit IgG was seen for all the three human IGF-IIR peptides synthesized: (1) 7~22AA, (2) 1103~1119AA and (3) 2046~2064AA. The antibody titer against peptide 2 was the highest (128 × 10 2 ), and the titer against peptide 1 was second (16 × 10 2 ) and the titer against peptide 3 was the lowest (4 × 10 2 ). A possibility of antibody cross-reactivity among the three peptides scarcely exists. That is why these antibodies were synthesized without identical sequences of amino acid residues for each. When the membrane, subjecte d to Western blotting afte r SDS electrophoresis of human placenta-derived acetone powder solution, was exposed to any of the three antibodies directed against peptides 1 through 3, a single band corresponding to IGF-IIR was seen at about 290 kDa. In normal rabbit serum without immunization, no single band was seen (Fig. 2) . In the preparation of human placentaderived acetone powder and purification of IGF-IIR, about 1 mg of purified IGF-IIR was obtained from 50 g of placental acetone powder, which was yielded by one human placenta (400~500 g) ( Fig.  3) . A smooth standard curve was obtained, indicating that the protocol used was valid (Fig. 4) . We tried this system on five human serum samples from healthy adults. The mean serum level of their soluble receptor was 724 ± 134 ng/ml (795, 559, 899, 628, 738 ng/ml), which are similar to the levels reported for. After SDS electrophoresis, a human serum sample was exposed to the antibody directed against peptide 2 (1103~1119AA), and a single band corresponding to soluble IGF-IIR was seen at about 220 kDa, which confirmed that the antibody reacted with soluble IGF-IIR in the serum (Fig. 5 ). We also compared the serum level of the soluble receptor before and after adding excess Fig. 3 The purification profile of human placenta-derived IGF-IIR. The human placenta-derived acetone powder was dissolved in buffer and applied to on M6P-affinity chromatography column. The absorbance of each fraction at 280 nm was measured. Fractions 6~12 corresponded to the IGF-IIR. Fig. 4 The standard curve in this competitive EIA to measure the blood level of IGF-IIR. Purified human placenta-derived IGF-IIR was coated onto the plate. Higher-purify human placentaderived IGF-IIR, diluted at 7 different ratios, was exposed to biotin-labeled antibody to peptide 2. HRP-labeled avidin was then added. Absorbance at 450 nm was measured. A smooth curve was obtained, indicating that this method was valid.
IGF-II and M6P to the serum sample. The excess volume of IGF-II and M6P was 2 × 10 6 times in the mol concentration against IGF-IIR before the addition. No significant difference in the level was detected (before IGF-II adding: 965, 1001, 30 ng/ ml, after IGF-II adding: 937, 994, 33 ng/ml, before 6MP adding: 972, 495, 97.1 ng/ml, after M6P adding: 964, 511, 105 ng/ml). We measured some of the same samples several times in two ways, in serum and plasma. No significant difference was found. Although we repeated freezing and thawing of human serum a few times without any particular preparation, the single band of 220 kDa was seen by Western blotting with this antibody for the soluble IGF-IIR at any time.
Discussion
The three antibodies to peptides of IGF-IIR in this study were purified IgG with Protein-G and the mixed antibodies to poly-L-lysine used as a carrier protein were removed with PLL-Sepharose. Western blotting was then done subjected with human placenta-derived acetone powder solution. A single band corresponding to IGF-IIR was seen at about 290 kDa for all three antibodies, and a s m o o t h s t an d ar d c u r v e wa s o b t ain ed . Consequently, we confirmed that the anti-1103~1119AA antibody employed in this system binds to the soluble form of IGF-IIR in serum in Western blotting. The single band was found at about 220 kDa and we can exactly measure the serum concentrations of the soluble form of human IGF-IIR.
According to recent reports, the extracellular domain of IGF-II/M6PR leaves the cell membrane and enters the blood circulation (9) (10) (11) . In circulating blood it retains the ability to bind to IGF-II with high affinity (5) and proteins with M6P moieties on their carbohydrate side chains, such as lysosomal enzymes (12), TGFβ precursor (13) , and proliferin (14) . While transporting enzymes to lysosomes, the IGF-IIR adjusts the blood level of IGF-II by incorporating IGF-II into cells for subsequent degradation. Moreover, the soluble form inhibits DNA synthesis by modifying the IGF-II action and by an IGF-independent mechanism (15) . It has also been confirmed that the levels of expression of the receptors in mother's serum and amniotic fluid decrease immediately after labor (16) .
Another study on the measurement of soluble IGF-IIR by Enzyme-linked immunosorbent assay was reported (18) . In that report, the solution including native IGF-IIR loaded onto the M6P affinity column was not derived from human placenta, but derived from hepatoma cells (HepG2). They then immunized rabbits with native whole IGF-IIR derived hepatoma cells instead of auto-synthesized peptides of IGF-IIR in our study. The blood level of the soluble IGF-IIR they found in healthy adults was 700 ± 230 ng/ml, which was near our 724 ± 134 ng/ml. In 1999, a quantitative analysis of soluble human IGF-II/M6P- R with high affinity antibodies to human IGF-II/ M6P-R detected in hen egg yolks by ELISA was done in 12 healthy people. They reported that the level of human IGF-II/M6P-R in the blood circulation was 1.8~5.4 µg/ml, and its mean was 3.6 µg/ml (17) . This blood level is five times as much as ours. In our EIA for the soluble form of IGF-IIR, the antibody employed has better specificity for IGF-IIR than the other systems previously reported, so our data must show the real level of the soluble form in circulating blood.
